KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Vertex Pharmaceuticals (VRTX) Gross Margin (2016 - 2025)

Historic Gross Margin for Vertex Pharmaceuticals (VRTX) over the last 16 years, with Q4 2025 value amounting to 85.39%.

  • Vertex Pharmaceuticals' Gross Margin fell 700.0% to 85.39% in Q4 2025 from the same period last year, while for Dec 2025 it was 86.24%, marking a year-over-year increase of 1300.0%. This contributed to the annual value of 86.24% for FY2025, which is 1300.0% up from last year.
  • Vertex Pharmaceuticals' Gross Margin amounted to 85.39% in Q4 2025, which was down 700.0% from 86.52% recorded in Q3 2025.
  • Over the past 5 years, Vertex Pharmaceuticals' Gross Margin peaked at 88.85% during Q1 2021, and registered a low of 85.38% during Q4 2023.
  • Moreover, its 5-year median value for Gross Margin was 87.28% (2021), whereas its average is 87.12%.
  • Per our database at Business Quant, Vertex Pharmaceuticals' Gross Margin skyrocketed by 7900bps in 2022 and then plummeted by -23100bps in 2023.
  • Over the past 5 years, Vertex Pharmaceuticals' Gross Margin (Quarter) stood at 88.06% in 2021, then dropped by 0bps to 87.7% in 2022, then dropped by -3bps to 85.38% in 2023, then grew by 0bps to 85.46% in 2024, then decreased by 0bps to 85.39% in 2025.
  • Its Gross Margin stands at 85.39% for Q4 2025, versus 86.52% for Q3 2025 and 86.25% for Q2 2025.